Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Acarix

0.27 SEK

+4.03 %

Less than 1K followers

ACARIX

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+4.03 %
+8.40 %
+1.12 %
-12.30 %
-5.57 %
+28.13 %
-48.86 %
-72.10 %
-96.33 %

Acarix is a diagnostics company. The company has developed a technology that enables the identification of coronary artery disease. The company's product is a non-invasive test that is applied with a patch to the patient to analyze sounds from the heart. The business is conducted primarily within the Nordic market. The company was founded in 2009 as a spin-off from Coloplast. The headquarters are located in Malmö.

Read more
Market cap
336.19M SEK
Turnover
565.43K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
7.5.
2026

Interim report Q1'26

13.5.
2026

General meeting '26

13.8.
2026

Interim report Q2'26

All
Press releases
ShowingAll content types
Press release2/13/2026, 12:05 PM

Redeye: Acarix (Q4 review): A solid end to 2025

Acarix
Regulatory press release2/12/2026, 7:00 AM

Acarix Publishes Year-End Report 2025

Acarix
Press release2/11/2026, 8:20 AM

Acarix Announces New Distribution Partner in Saudi Arabia for the CADScor System

Acarix

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release2/4/2026, 8:20 AM

Acarix Receives EU MDR Certification for the CADScor®System

Acarix
Regulatory press release12/8/2025, 7:47 AM

ACARIX CARRIES OUT A DIRECTED SHARE ISSUE OF APPROX. SEK 33.4 MILLION

Acarix
Press release11/6/2025, 7:45 AM

Invitation to presentation of Acarix´s third quarter 2025 report

Acarix
Regulatory press release11/6/2025, 7:00 AM

Acarix Publishes Interim Report, Third quarter 2025

Acarix
Regulatory press release10/27/2025, 2:35 PM

Announcement from the general meeting in Acarix AB

Acarix
Regulatory press release10/24/2025, 1:15 PM

Acarix AB changes Certified Adviser to Tapper Partners AB

Acarix
Press release10/17/2025, 6:30 AM

Acarix responds to G-BA decision on reimbursement in the German market

Acarix
Regulatory press release10/9/2025, 10:15 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN ACARIX AB

Acarix
Press release10/7/2025, 7:31 AM

Acarix CADScor® System Gains HealthChoice Reimbursement Coverage

Acarix
Press release9/18/2025, 3:04 PM

Acarix Chairman Jan Poulsen Acquires Shares

Acarix
Press release9/8/2025, 7:45 AM

CEO purchases shares in Acarix

Acarix
Press release8/25/2025, 9:19 AM

Redeye: Acarix Q2 - An eventful quarter

Acarix
Press release8/21/2025, 6:30 AM

Acarix Reports Significant Progress Toward Fixed Reimbursement

Acarix
Regulatory press release8/21/2025, 6:00 AM

Acarix Publishes Interim Report, January – June 2025

Acarix
Press release8/20/2025, 7:45 AM

Acarix and Aalborg University Abstract Accepted for AHA 2025

Acarix
Press release8/18/2025, 9:09 AM

Invitation to presentation of Acarix´s second quarter 2025 report

Acarix
Press release7/28/2025, 7:47 AM

Acarix achieves new Fixed U.S. reimbursement milestone for CADScor at $300.00 USD

Acarix
Forum discussions
On my journey in search of a new Revenio, in a country where vague Finland-Swedish was spoken and which was ruled by Carl XVI Gustaf, I came across a company called Acarix. And I’m not comparing this to be a new Revenio. For the diagnosis of coronary artery disease, a common basic...
9/8/2021, 5:11 AM
by Fisu
9
Odotettu 79 MSEK osakeanti nyt käynnissä: acarix.com Acarix | CADScor®System
12/6/2021, 12:06 AM
by Pohjolan Eka
3
Tärkeimmät talousuutiset | Kauppalehti Acarix CADScor®System included in NICE guidelines (UK) Tärkeimmät ajankohtaiset talousuutiset, pörssikurssit ja kattavat sijoittajapalvelut löydät Kauppalehdestä. Tuossa hieman vanhempaa tiedotetta. Mielenkiintoinen tuote, joka on tutkimuksissa...
9/8/2021, 7:32 AM
by PP2020
3
Mielenkiintoista, että analyytikkofirma on myös neuvonantajana… Onkohan sijoittajana myös.?
9/8/2021, 5:33 AM
by Yoda
3
Redeye:n sivuilta kyllä ko. Yhtiön kohdalta löytyy Disclosures joka kertoo omistaako Redeye yhtiötä. Tässä tapauksessa ei omista. redeye.se Acarix Disclosures - Redeye Discover the latest equity research on Acarix.
9/8/2021, 2:45 PM
by Llopardi
2
PubMed Economic Analysis of the CADScor System for Ruling Out Coronary Artery... The CADScor System is a potentially cost-saving test for the diagnosis of CAD. When initiated before the use of non-invasive cardiac imaging tests such as computed tomography coronary angiography, the...
9/8/2021, 5:40 AM
by PP2020
2
Uutista Amerikan mailta on tullut, en osaa sitä tänne siirtää. Kiitos jo etukäteen
10/27/2021, 11:02 AM
by Hollitupa
1
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.